Phuturdex › Diseases › Arterial hypertension
Drugs in development · updated 30 October 2026
Arterial hypertension: drugs in development
As of 30 October 2026 there are 94 active clinical trials (recruiting or ongoing, phases I–III) on 119 drugs for arterial hypertension. 73 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 73 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AmlodipineSdamlo®, Norliqva® | III | 5 | NCT06150560 |
| BaxdrostatBaxfendy® | III | 3 | NCT06742723 |
| DapagliflozinForxiga, Dapagliflozin Propanediol | III | 3 | NCT06742723 |
| DexmedetomidineIgalmi®, Precedex® | II–III | 3 | NCT06935292 |
| LosartanArbli®, Cozaar® | III | 3 | NCT06150560 |
| OrforglipronFoundayo® | III | 3 | NCT06952530 |
| AlcoholEthanol, Dehydrated alcohol | III | 2 | NCT07083765 |
| Candesartan | III | 2 | NCT06646354 |
| EmpagliflozinJardiance | III | 2 | NCT07064473 |
| EzetimibeEzetemibe, Zetia® | III | 2 | NCT06646354 |
| BupropionForfivo Xl®, Aplenzin® | III | 1 | NCT07806279 |
| EnalaprilEpaned®, Aqumeldi® | III | 1 | NCT07222852 |
| LabetalolLabetalol Hydrochloride In Sodium Chloride®, Labetalol Hydrochloride In Dextrose® | III | 1 | NCT05551104 |
| NifedipineAdalat Cc®, Procardia Xl® | III | 1 | NCT05551104 |
| RosuvastatinEzallor Sprinkle®, Crestor® | III | 1 | NCT06646354 |
Sorted by most advanced phase and number of active trials. Showing 15 of 46 drugs.
All 119 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Pulmonary hypertension 38 drugs
- Essential hypertension 31 drugs
- Interstitial lung disease 65 drugs
- Arterial pulmonary hypertension 27 drugs
- Chronic obstructive pulmonary disease 89 drugs
- Cardiovascular disease 71 drugs
- Lung disease 104 drugs
- Hypertension, Pregnancy-Induced 7 drugs
- Vascular disease 16 drugs
- Fibrosis 52 drugs
- Heart failure 104 drugs
- Pre-eclampsia 23 drugs
Broader categories
- Vascular disease 16 drugs
- Cardiovascular disease 71 drugs
- Nutritional and metabolic diseases 5 drugs
- Metabolic disease 30 drugs
- Female urogenital diseases and pregnancy complications 3 drugs
- Urogenital Diseases 16 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D006973 “Hypertension”.